Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.54 |
| ▸ | ALPI | P09923 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | XIAP | P98170 | 1/20 | 0.54 |
| ▸ | TPH1 | P17752 | 4/20 | 0.51 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3833206 | 0.89 | ALDH1A1 (0.51) | SLC7A5TPH1LDHA | |
| SCHEMBL3835529 | 0.87 | TPH1 (0.45) | TPH1LDHA | |
| SCHEMBL22190064 | 0.83 | GRIA2 (0.60) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL7349516 | 0.83 | TPH1 (0.57) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL7349532 | 0.83 | TPH1 (0.57) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL22190065 | 0.83 | GRIA2 (0.60) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL7227087 | 0.83 | ITGB1 (0.56) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL5162726 | 0.83 | ITGB1 (0.56) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL3833211 | 0.82 | ITGB1 (0.50) | LDHA | |
| Hydrochloric Acid SCHEMBL5159881 | 0.82 | ITGB1 (0.55) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786177-B2 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7645770-B2 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2010-01-12 | — | — | US | disclosed |
| US-20090186914-A1 | Phenylalanine Enamide Derivatives | UCB PHARMA, S.A. (BE) | 2009-07-23 | — | — | US | disclosed |
| US-7531549-B2 | Phenylalanine enamide derivatives | UCB PHARMA, S.A. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-20090105291-A1 | Phenylalanine Enamide Derivatives | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| EP-1780201-A2 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | Celltech R&D Limited (GB) | 2007-05-02 | — | — | EP | disclosed |
| EP-1370531-B1 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | CELLTECH R&D LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-20070027174-A1 | Phenylalanine Enamide Derivatives | CELLTECH R&D LIMITED | 2007-02-01 | — | — | US | disclosed |
| US-7122556-B2 | Phenylalanine enamide derivatives | CELLTECH R&D LIMITED (GB) | 2006-10-17 | — | — | US | disclosed |
| US-6878718-B2 | Phenylalanine enamide derivatives | CELLTECH R&D LIMITED (GB) | 2005-04-12 | — | — | US | disclosed |
| US-20050038084-A1 | Phenylalanine enamide derivatives | CELLTECH R&D LIMITED | 2005-02-17 | — | — | US | disclosed |
| EP-1370531-A1 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | Celltech R & D Limited (GB) | 2003-12-17 | — | — | EP | disclosed |
| US-20020169336-A1 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2002-11-14 | — | — | US | disclosed |
| WO-2002068393-A1 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | CELLTECH R & D LIMITED (GB) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027174-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, AGTR2 | SLC7A5 942/4885ALPI 1285/4885PKM 1489/4885 |
| US-20090105291-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, PRLHR | SLC7A5 1081/4885ALPI 1471/4885PKM 1013/4885 |
| US-20050038084-A1 | Phenylalanine enamide derivatives | PAH, ARRB1, ACVR2B | SLC7A5 1024/4885ALPI 1700/4885PKM 1537/4885 |
| US-20020169336-A1 | Phenylalanine enamide derivatives | CCR1, AHR, PAH | SLC7A5 1667/4885ALPI 1734/4885PKM 1945/4885 |
| US-20090186914-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, PRLHR | SLC7A5 1081/4885ALPI 1471/4885PKM 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.